Immunotherapy has transformed the treatment landscape of many cancers, with durable
responses in disease previously associated with a poor prognosis. Patient selection remains …

Lung cancer continues to be the leading cause of cancer-related death in the world, which is
classically subgrouped into two major histological types: Non-small cell lung cancer …

Background Currently, only a fraction of patients with non-small cell lung cancer (NSCLC)
treated with immune checkpoint inhibitors (ICIs) experience a durable clinical benefit (DCB) …

Purpose In the present study, we aimed to evaluate the expression of programmed death-
ligand 1 (PD-L1) in patients with non-small cell lung cancer (NSCLC) by radiomic features of …

Immunotherapies are leading to improved outcomes for many cancers, including those with
devastating prognoses. As therapies like immune checkpoint inhibitors (ICI) become a …

Background In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …

Cancer immunotherapy, especially immune-checkpoint inhibitors (ICIs), has paved a new
way for the treatment of many types of malignancies, particularly advanced-stage cancers …

Purpose Programmed cell death protein-1 ligand (PD-L1) is an important prognostic
predictor for immunotherapy of non-small cell lung cancer (NSCLC). This study aimed to …

Body mass index (BMI) is well known to be associated with poor prognosis in several
cancers. The relationship between BMI and the long-term outcomes of patients with …

Purpose This study aimed to evaluate the clinical feasibility of early 30-minute dynamic 2-
deoxy-2-[18F] fluoro-D-glucose (18F-FDG) positron emission tomography (PET) scanning …